Monitoring Alzheimer’s Disease via Ultraweak Photon Emission

Abstract

The present study takes on an innovative experiment involving detection of ultraweak photon emission (UPE) from the hippocampus of male rat brains and finds significant correlations between Alzheimer's disease (AD), memory decline, oxidative stress, and the intensity of UPE emitted spontaneously from the hippocampus. These remarkable findings opens up novel methods for screening, detecting, diagnosing and classifying neurodegenerative diseases (and associated sydromes), such as in AD. This also paves the way towards novel advanced brain-computer interfaces (BCIs) photonic chip for the detection of UPE from brain's neural tissue. The envisaged BCI photonic chip (BCIPC) would be minimally invasive, cheap, high-speed, scalable, would provide high spatiotemporal resolution of brain's activity and would provide short- and long-term screening of clinical patho-neurophysiological signatures, which could be monitored by a smart wristwatch or smartphone via a wireless connection.

Reduced biophotonic activities and spectral blueshift in Alzheimer’s disease and vascular dementia models with cognitive impairment

“…In the present study, reduced biophotonic activities and spectral blueshift induced by glutamate were found in synaptosomes and brain slices from AD and VaD model animals, indicating that this biophoton imaging technology is accurate and effective in assessing functional changes in synapses and neural circuits. Recently, Sefati et al detected the ultraweak photon emission (UPE) of rat hippocampus after injection of streptozotocin (STZ) and donepezil via a photomultiplier tubes (PMT) device, suggesting that UPE can be used for screening and diagnosing AD ( Sefati et al, 2023 ). This further supports that the biophoton imaging technology could serve as a non-invasive method for studying brain functions and diseases related to cognitive impairment.…”